TSLA
Tesla
-- 231.300 NVDA
NVIDIA
-- 110.165 PLTR
Palantir
-- 79.120 AAPL
Apple
-- 221.880 MSTR
Strategy
-- 244.100 
NEWS ER
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
Positive
Secured significant financing of up to $275 million, including $110 million immediate private placement
Received FDA Study May Proceed letter for IkT-001Pro PAH trial
High trial completion rate with 120 of 126 patients completing the Phase 2 201 Trial
Positive
Secured significant financing of up to $275 million, including $110 million immediate private placement
Received FDA Study May Proceed letter for IkT-001Pro PAH trial
High trial completion rate with 120 of 126 patients completing the Phase 2 201 Trial
Negative
Increased net loss to $5.8 million in Q3 2024 from $4.6 million in Q3 2023
R&D expenses increased to $4.2 million from $3.23 million year-over-year
Low cash position of $3.2 million as of September 30, 2024
Increased net loss to $5.8 million in Q3 2024 from $4.6 million in Q3 2023
R&D expenses increased to $4.2 million from $3.23 million year-over-year
Low cash position of $3.2 million as of September 30, 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment